Clinical Trials Sponsored by Progen Pharmaceuticals

Total 21393 results

Urigen

Completed

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

United States
Biogen

Completed

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

Drug Interactions

United States
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Biogen

Completed

Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy (RELAY-1)

Lumbosacral Radiculopathy

Spain, United Kingdom, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Italy, Latvia, Netherlands, Romania, Serbia, Slovakia
Biogen

Completed

Ireland Natalizumab (TYSABRI) Observational Program (iTOP)

Relapsing-Remitting Multiple Sclerosis

Ireland
Biogen

Completed

Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074

Drug Interaction

United States
Biogen

Completed

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

Healthy | Sjögren's Syndrome | Sicca Syndrome

United States
Biogen

Completed

A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia

Primary Inherited Erythromelalgia

United States
Biogen

Terminated

Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects

Neuropathic Pain | Pain, Neuropathic
Biogen

Completed

GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers

Bipolar Disorder

United Kingdom
Biogen

Completed

Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Lumbosacral Radiculopathy

Sweden, France, Czechia, Denmark
Biogen

Completed

PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers

Trigeminal Neuralgia

United Kingdom
Biogen

Terminated

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

Secondary Progressive Multiple Sclerosis

United States, Finland, Italy, Spain, Canada, France, Israel, Sweden, Netherlands, Belgium, Poland, United Kingdom, Czechia, Denmark, Russian Federation, Germany, Ireland
Biogen

Terminated

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (REVEAL)

Relapsing-Remitting Multiple Sclerosis

United States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
Biogen

Terminated

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (ESCALATE)

Relapsing Multiple Sclerosis

United States
Biogen

Terminated

Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.

Multiple Sclerosis

United States
Biogen

Terminated

Tecfidera Slow-Titration Study (TITRATION)

Multiple Sclerosis

United States, Belgium, Czech Republic, Italy
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Biogen

Completed

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (EFFECT)

Multiple Sclerosis

United States, Italy, Hungary, United Kingdom, Spain, France, Australia, Germany, Canada, Switzerland, Argentina, Czech Republic, Croatia
Biogen

Completed

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (MANAGE)

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Biogen

Completed

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (ALLOW)

Relapsing Multiple Sclerosis

United States
Biogen

Terminated

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (ATLAS)

Lupus Nephritis

United States, Peru, Belgium, Italy, Philippines, Malaysia, Hong Kong, Argentina, Germany, Hungary, Australia, Colombia, Russian Federation, Portugal, Mexico, Korea, Republic of, France, Thailand, Brazil, Poland, Spain
Biogen

Terminated

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Lupus Nephritis

Belgium, Peru, Italy, Malaysia, Australia, Argentina, United States, Hong Kong, Hungary, Poland, Colombia, Russian Federation, Philippines, Brazil, France, Korea, Republic of, Mexico, Spain, Thailand
Biogen

Completed

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Alzheimer's Disease

United States
Biogen

Terminated

Fampridine Pregnancy Exposure Registry

Multiple Sclerosis | Pregnancy

France
Biogen

Completed

Tecfidera Lymphocyte Chart Review (REALIZE)

Multiple Sclerosis

United States
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Healthy

United States
Biogen

Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (STRATEGY)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Withdrawn

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
Biogen

Terminated

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

Rheumatoid Arthritis

United States, Belgium, Canada, United Kingdom
Biogen

Completed

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants (RESPOND)

Rheumatoid Arthritis

Argentina, Mexico, Romania, Brazil, Hungary, Poland, Russian Federation, United Kingdom
Biogen

Terminated

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (COSTAN)

Relapsing-Remitting Multiple Sclerosis

Canada
Biogen

Completed

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Breast Cancer

United States, Russian Federation, Australia, Belgium
Biogen

Terminated

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)

Chronic Lymphocytic Leukemia

United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Lithuania, Poland, Romania, Australia, Argentina, Austria, Canada, France, Israel, New Zealand, Portugal, Slovakia, Greece, Germany, India, Bel...
Biogen

Completed

TYSABRI Global Observational Program in Safety (TYGRIS)

Multiple Sclerosis

United States
Biogen

Completed

Functional MRI in Lupus Nephritis

Healthy | Lupus Nephritis

United States
Biogen

Completed

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Alzheimer's Disease

United States
Biogen

Completed

BG00012 Regional Absorption Study

Healthy

United Kingdom
Biogen

Completed

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Healthy | Painful Lumbar Radiculopathy

Netherlands
Biogen

Completed

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Healthy

United States
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Biogen

Terminated

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Progressive Multifocal Leukoencephalopathy

United States, Germany
Biogen

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

Sciatica

Netherlands
Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (JEMS)

Multiple Sclerosis
Biogen

Completed

A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers

Healthy | Renal Insufficiency
Biogen

Completed

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Healthy

United States
Biogen

Completed

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta (RENeu)

Relapsing-Remitting Multiple Sclerosis

New Zealand, Australia
Biogen

Completed

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (Avonex China)

Multiple Sclerosis

China

3

Subscribe